Effectiveness of E-prf Alone and in Combination With Bioactive Glass Nanoparticles in Grade II Furcation Defects
NCT ID: NCT07042204
Last Updated: 2026-01-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2024-01-03
2025-08-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Growth Factors Release of PRF and PRGF
NCT02447510
Efficacy of HA Gel Injection Versus Multilayer (L-PRF) in the Interdental Papilla Reconstruction
NCT05953896
The Use of Leucocyte Platelet Rich Fibrin (L- PRF) Covered Perforated Guided Tissue Membrane for Treatment of Periodontal Intrabony Defects
NCT04576468
Extended Platelet- Rich Fibrin Membrane Combined With Vestibular Incision Subperiosteal Tunnel Access Technique to Treat Localized Gingival Recession
NCT07079293
Furcation Treatment With L-PRF and aPDT
NCT04842188
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Group I: 10 grade II furcation defects will be treated by extended platelet-rich fibrin (ePRF) alone.
Group II: 10 grade II furcation defects will be treated by bioactive glass nanoparticles mixed with extended platelet-rich fibrin (BGn+ePRF).
Group III: 10 grade II furcation defects will be treated by bioactive glass nanoparticles with collagen membrane.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group I
10 grade II furcation defects will be treated by extended platelet-rich fibrin (ePRF) alone.
Group I (extended platelet-rich fibrin)
mucoperiosteal flap will be raised through sulcular incisions Debridement of granulation tissue from the osseous defect and furcation will be filled with (ePRF) at the first group
Group II
10 grade II furcation defects will be treated by bioactive glass nanoparticles mixed with extended platelet-rich fibrin (BGn+ePRF).
Group II (bioactive glass nanoparticles mixed with extended platelet-rich fibrin)
bioactive glass nanoparticles mixed with extended platelet-rich fibrin (BGn+ePRF)
Group III
10 grade II furcation defects will be treated by bioactive glass nanoparticles with collagen membrane.
Group III (bioactive glass nanoparticles and covered by a collagen membrane)
bioactive glass nanoparticles and covered by a collagen membrane
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Group I (extended platelet-rich fibrin)
mucoperiosteal flap will be raised through sulcular incisions Debridement of granulation tissue from the osseous defect and furcation will be filled with (ePRF) at the first group
Group II (bioactive glass nanoparticles mixed with extended platelet-rich fibrin)
bioactive glass nanoparticles mixed with extended platelet-rich fibrin (BGn+ePRF)
Group III (bioactive glass nanoparticles and covered by a collagen membrane)
bioactive glass nanoparticles and covered by a collagen membrane
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patients are in good systemic health and had not undergone any periodontal surgery in the areas to be treated within the prior 12 months.
Exclusion Criteria
* Patients that take any medications within the past 6 months that could alter their periodontal status.
* pregnant or lactating females.
* Patients with known allergy to materials or drugs that will be used or prescribed in this study.
18 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merna Nasser Mohamed Mostafa Ibrahim Elnahas
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Merna Nasser Mohamed Mostafa Ibrahim Elnahas
BDS, Clinical demonstrator, Oral Medicine, Periodontology, Diagnosis and Oral Radiology Department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Merna N Elnahas, Master's degree
Role: PRINCIPAL_INVESTIGATOR
Mansoura Unniversity
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mansoura University
Al Mansurah, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A03011023OM
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.